Targeted therapeutics designed to address unmet needs in immune-mediated diseases

We have a robust pipeline of therapeutic development programs to address several clinical IBD patient subpopulations, and plan to develop a companion diagnostic for each program.

Prometheus Biosciences therapeutic pipeline

ProgramIndicationPreclinicalPhase 1Phase 2Phase 3
TL1A mAb
Ulcerative Colitis
Crohn's Disease
CD30 ligand mAb
Immune-Mediated Diseases
Cytokine receptor mAb
Immune-Mediated Diseases
Inflammatory cytokine mAb
Immune-Mediated Diseases
GPCR small molecule
Immune-Mediated Diseases

*Partnered with Dr. Falk Pharma in Europe, Australia, and New Zealand

Strategic collaborations and partnerships

To advance our game-changing precision medicines platform, we have forged partnerships with pharmaceutical companies, foundations, and academic groups with critical gastrointestinal (GI) area expertise and resources. This approach has accelerated the application of our technology and enabled us to secure necessary funding to advance our development progress.

Our partners include Cedars-Sinai Medical Center, University of California San Diego, and Dr. Falk Pharma GmbH.

Partnership inquiries

We strive to be the partner of choice in gastrointestinal (GI) and immune-mediated diseases by applying our technology and utilizing the Prometheus360™ platform to advance clinical programs. For inquiries or to learn more, please contact us.

Prometheus Biosciences
3050 Science Park Rd.
San Diego, CA 92121